Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Formulations and Dose Escalation in Obesity
NCT07150962Phase 1Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of HRS9531 in obesity (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Area under the curve from Time Zero to Time of last quantifiable concentration at Day 15, Adverse event and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07150962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150962.